Alkem Laboratories on Saturday informed the stock exchanges that the Ministry of Health, Armenia has completed a Good Manufacturing Practices (GMP) inspection at the company’s manufacturing facility located in Sikkim, India. The inspection, which was carried out from 21 November 2025 to 22 November 2025, concluded without any critical or major observations, signalling a clean outcome for the pharmaceutical firm.
In its official communication addressed to both the BSE and the National Stock Exchange of India, the company confirmed that the audit was conducted over two days and has now been formally closed. The update was issued by Manish Narang, President – Legal, Company Secretary and Compliance Officer at Alkem Laboratories. The letter emphasised that the inspection ended “with no critical or major observation”, indicating that the facility met the compliance standards evaluated by the Armenian health authorities.
GMP inspections conducted by international regulatory bodies are integral to ensuring quality, safety and manufacturing consistency across pharmaceutical production lines. A favourable outcome, such as the one reported by Alkem, strengthens the company’s regulatory track record and supports the continuity of exports to markets that rely on compliance with external health agencies.
Alkem requested the exchanges to take note of the development, marking yet another regulatory milestone for the company’s Sikkim operations.
